Originalbeitrag in Fachzeitschrift
A molecularly engineered, broad-spectrum anti-coronavirus lectin inhibits SARS-CoV-2 and MERS-CoV infection in vivo
Chan J, Oh Y, Yuan S, Chu H, Yeung M, Canena D, et al. A molecularly engineered, broad-spectrum anti-coronavirus lectin inhibits SARS-CoV-2 and MERS-CoV infection in vivo. Cell Reports Medicine. 2022;3(10):100774. doi:https://doi.org/10.1016/j.xcrm.2022.100774
BOKU Autor*innen
Miriam Klausberger
Dipl.-Ing. Miriam Klausberger Ph.D.
Johannes Stadlmann
Assoc. Prof. Priv.Doz. DI Dr. Johannes Stadlmann
Chris Oostenbrink
Univ.Prof. Dr. Chris Oostenbrink
